A study published in the Journal of the National Cancer Institute in 2000 (PMID: 10675382) examined the effects of hormone replacement therapy (HRT) on breast cancer risk among postmenopausal women aged 55-72. The analysis of 1,897 breast cancer cases and 1,637 controls found that combined HRT (estrogen plus progestin) increased
This review examines the impact of hormone replacement therapy (HRT) on inflammatory biomarkers associated with cardiovascular disease in postmenopausal women. It highlights how different HRT regimens influence markers like E-selectin, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin-6, transforming growth factor-alpha, and C-reactive protein (CRP). Oral conjugated estrogens increase CRP levels,
This review discusses the use of bioidentical hormones for menopausal therapy, criticizing the assumption that they are safer than synthetic hormones. Despite some proponents advocating for their use, particularly through salivary hormone testing, the review finds insufficient evidence to support their superiority or safety compared to synthetic options. Providers should
This review article discusses the potential impact of combining testosterone with estrogen in hormone replacement therapy for postmenopausal women and its associated risks, including breast cancer. It emphasizes the need for careful evaluation when using testosterone therapy alongside estrogen, especially for women with low sexual desire disorder, highlighting the importance
This article reviews the relationship between postmenopausal hormone therapy and breast cancer risk. It finds that estrogen alone may slightly reduce breast cancer risk, while combined estrogen-progestin therapy significantly increases it. Notably, current estrogen-progestin use is linked to a higher risk of lobular cancer than ductal cancer, although the risk
This case-control study investigated the relationship between combined estrogen and progestin hormone replacement therapy (HRT) and breast cancer risk in middle-aged women. The study found no significant increase in breast cancer risk for women using HRT, with a potential reduction in risk for long-term users. These findings suggest that combined
